JNJ JOHNSON & JOHNSON
Pharmaceutical Preparations · NYSE · SEC CIK 200406 · Fiscal year ends 01/03
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.8%
TTM net income YoY-35.9%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR5.9%
Net income 3-yr CAGR-22.5%
Margins
Gross margin67.6%
Operating margin—
Net margin16.2%
FCF margin20.7%
EBITDA margin—
Returns
ROE20.0%
ROA8.2%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets58.7%
Debt / equity0.55x
Current ratio1.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.63x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-27 | 2026Q22026-06-28 | 2026Q12026-03-29 | 2025Q4*2025-12-28 | 2025Q32025-09-28 | 2025Q22025-06-29 | 2025Q12025-03-30 | 2024Q4*2024-12-29 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $25.40B | $25.31B | $24.06B | $24.56B | $23.99B | $23.74B | $21.89B | $22.52B |
| Cost of revenue | $8.10B | $8.05B | $8.11B | $7.97B | $7.30B | $7.63B | $7.36B | $7.13B |
| Gross profit | $17.30B | $17.26B | $15.96B | $16.60B | $16.69B | $16.11B | $14.54B | $15.39B |
| R&D expense | $4.65B | $3.65B | $3.53B | -$10.30B | $3.67B | $3.52B | $3.23B | -$10.09B |
| SG&A expense | $6.29B | $6.43B | $6.03B | $6.75B | $5.92B | $5.89B | $5.11B | $6.45B |
| Interest expense | $217.00M | $281.00M | $272.00M | $214.00M | $245.00M | $308.00M | $204.00M | $137.00M |
| Pretax income | $34.00M | $6.75B | $5.99B | $4.97B | $7.49B | $6.49B | $13.63B | $3.89B |
| Income tax | -$176.00M | $1.21B | $755.00M | -$150.00M | $2.34B | $954.00M | $2.63B | $456.00M |
| Net income | $210.00M | $5.53B | $5.24B | $5.12B | $5.15B | $5.54B | $11.00B | $3.43B |
| EPS (basic) | 0.09 | 2.30 | 2.17 | — | 2.14 | 2.30 | 4.57 | — |
| EPS (diluted) | 0.09 | 2.27 | 2.14 | — | 2.12 | 2.29 | 4.54 | — |
| Dividends declared per share | 1.34 | 1.34 | 1.30 | 1.30 | 1.30 | 1.30 | 1.24 | 1.24 |
| Weighted avg. shares (diluted) | 2.45B | 2.44B | 2.45B | — | 2.43B | 2.42B | 2.42B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16.91B | $20.42B | $21.69B | $19.71B | $18.23B | $18.58B | $38.47B | $24.11B |
| Short-term investments | $318.00M | $336.00M | $363.00M | $393.00M | $331.00M | $303.00M | $307.00M | $417.00M |
| Receivables | $18.99B | $19.05B | $17.72B | $17.18B | $17.61B | $17.85B | $16.02B | $14.84B |
| Inventory | $15.38B | $15.14B | $14.58B | $14.19B | $14.15B | $13.41B | $12.66B | $12.44B |
| Current assets | $56.35B | $59.77B | $59.17B | $55.62B | $54.61B | $54.50B | $71.55B | $55.89B |
| PP&E, net | $24.10B | $23.58B | $23.27B | $23.17B | $22.34B | $21.95B | $20.87B | $20.52B |
| Goodwill | $48.47B | $48.48B | $48.56B | $48.77B | $48.05B | $48.12B | $44.47B | $44.20B |
| Intangibles | $46.65B | $48.23B | $49.06B | $50.40B | $48.74B | $49.84B | $36.76B | $37.62B |
| Total assets | $197.43B | $201.06B | $200.89B | $199.21B | $192.82B | $193.39B | $193.67B | $180.10B |
| Current liabilities | $55.46B | $54.90B | $57.72B | $54.13B | $50.87B | $54.18B | $56.90B | $50.32B |
| Short-term debt | $8.85B | $11.69B | $17.46B | $8.49B | $6.39B | $11.53B | $13.90B | $6.00B |
| Long-term debt | $35.80B | $37.34B | $37.53B | $39.44B | $39.41B | $39.23B | $38.35B | $30.65B |
| Total debt | $44.65B | $49.04B | $54.99B | $47.93B | $45.80B | $50.76B | $52.25B | $36.65B |
| Total liabilities | $115.90B | $116.09B | $119.71B | $117.67B | $113.54B | $114.92B | $115.56B | $108.61B |
| Shareholders' equity | $81.53B | $84.97B | $81.19B | $81.54B | $79.28B | $78.47B | $78.11B | $71.49B |
| Net debt | $27.74B | $28.61B | $33.30B | $28.22B | $27.56B | $32.18B | $13.78B | $12.55B |
| Cash flow statement | ||||||||
| Operating cash flow | $7.72B | $8.62B | $2.51B | $7.31B | $9.17B | $3.88B | $4.17B | $6.98B |
| Capital expenditure | $1.36B | $1.32B | $1.05B | $1.84B | $1.16B | $1.04B | $795.00M | $1.61B |
| Free cash flow | $6.36B | $7.29B | $1.47B | $5.47B | $8.01B | $2.83B | $3.38B | $5.37B |
| Investing cash flow | -$2.71B | -$1.11B | -$1.04B | -$4.49B | -$542.00M | -$18.26B | -$297.00M | -$1.32B |
| Financing cash flow | -$8.53B | -$8.78B | $530.00M | -$1.37B | -$8.93B | -$5.67B | $10.42B | -$1.34B |
| Depreciation & amortization | $2.12B | $1.96B | $2.00B | $2.01B | $1.78B | $1.94B | $1.77B | $1.90B |
| Stock-based compensation | $357.00M | $458.00M | $300.00M | $309.00M | $347.00M | $410.00M | $288.00M | $238.00M |
| Share buybacks | $1.71B | $221.00M | $4.03B | $1.92B | $1.90B | $0 | $2.13B | $282.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.